Sixten Körper, Bernd Jahrsdörfer, Victor M Corman, Jan Pilch, Patrick Wuchter, Rainer Blasczyk, Rebecca Müller, Torsten Tonn, Tamam Bakchoul, Richard Schäfer, David Juhl, Tatjana Schwarz, Nina Gödecke, Thomas Burkhardt, Michael Schmidt, Thomas Appl, Hermann Eichler, Harald Klüter, Christian Drosten, Erhard Seifried, Hubert Schrezenmeier
BACKGROUND: Convalescent plasma is one of the treatment options for COVID-19 which is currently being investigated in many clinical trials. Understanding of donor and product characteristics is important for optimization of convalescent plasma. METHODS: Patients who had recovered from CO-VID-19 were recruited as donors for COVID-19 convalescent plasma (CCP) for a randomized clinical trial of CCP for treatment of severe COVID-19 (CAPSID Trial). Titers of neutralizing antibodies were measured by a plaque-reduction neutralization test (PRNT)...
May 2021: Transfusion Medicine and Hemotherapy